Anticancer C Met Inhibitor SU11606 Cas 669764-17-4
Anticancer C Met Inhibitor SU11606 Cas 669764-17-4
+ AII PRODUCTS
- Prostaglandins - Custom Synthesis - PARP Inhibitors - PI3K Inhibitors - FAK Inhibitors - AKT Inhibitors - C-Kit Inhibitors - VEGFR Inhibitors - c-Met Inhibitors - CDK Inhibitors - CYP17 Inhibitors - DNA/RNA Inhibitors - mTOR Inhibitors - SRC Inhibitors - Others
Product
|
Size |
Price |
Stock |
Quantity |
|---|---|---|---|
|
Get Quotation Now Add to Cart Bulk Inquiry |
|||
AddThis Sharing Buttons
Share to FacebookFacebookShare to TwitterTwitterShare to PrintPrintShare to EmailEmailShare to PinterestPinterestShare to GmailGmailShare to LinkedInLinkedInShare to Email AppEmail AppShare to TumblrTumblrShare to MoreAddThis
Shipping and handling fee USD40, Free delivery is qualified when the total value of your order exceeds USD500.If the item is temporarily out of stock. Please email to order@pharm-intermediates.com,we will inform you when we have it in stock.
Chemical Information
|
Product name:SU11606 |
Purity:98% min |
|
CAS NO:669764-17-4 |
Solubility:Soluble in DMSO |
|
Molecular Formula:C29H33ClN4O4S |
Package:Package according to customer requirements |
|
Molecular Weight:569.11472 |
Storage:Store at -20℃ |
Quality control
Remarks
SU11606 is a potent c-MET inhibitor with potential anticancer activity.
IUPAC/Chemical Name: (Z)-N-(3-chlorophenyl)-3-((3,5-dimethyl-4-(3-morpholinopropyl)-1H-pyrrol-2-yl)methylene)-N-methyl-2-oxoindoline-5-sulfonamide
InChi Key: JXOCDHNKTVLZLD-ITYLOYPMSA-N
InChi Code: InChI=1S/C29H33ClN4O4S/c1-19-24(8-5-11-34-12-14-38-15-13-34)20(2)31-28(19)18-26-25-17-23(9-10-27(25)32-29(26)35)39(36,37)33(3)22-7-4-6-21(30)16-22/h4,6-7,9-10,16-18,31H,5,8,11-15H2,1-3H3,(H,32,35)/b26-18-
SMILES Code: O=S(C1=CC2=C(NC(/C2=CC3=C(C)C(CCCN4CCOCC4)=C(C)N3)=O)C=C1)(N(C5=CC=CC(Cl)=C5)C)=O
Related Products
Capmatinib; MK-8033; Merestinib; SGX-523; MDK-0264; Tepotinib; NPS-1034; WYE-125132; PHA-665752; SCR-1481B1
References
1. Golub, Todd; Straussman, Ravid. Methods of treating cancer using a chemotherapeutic agent with an agent that blocks the activity of hepatocyte growth factor or its cognate receptor c-MET. From PCT Int. Appl. (2012), WO 2012178038 A1 20121227.
2. Smith, David; Hussain, Maha. Dual inhibitors of Met and VEGF for the treatment of castration resistant prostate cancer and osteoblastic bone metastases. PCT Int. Appl. (2012), WO 2012044577 A1 20120405
Get in Touch
Have questions about our products or want to discuss a custom order? Our team is ready to help you.